# Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

> **NCT04149067** · — · COMPLETED · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 1080 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT04149067
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-05
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 1080 (ACTUAL)
- **Last updated:** 2019-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04149067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04149067, "Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04149067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*